EDAP TMS is a holding company. Through its subsidiaries, Co. is engaged in the development, production, marketing, distribution and maintenance of a portfolio of minimally-invasive medical devices for the treatment of urological diseases. Co. has two reporting segments: the High Intensity Focused Ultrasound (HIFU) division, which develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology; and the Urological Devices and Services division, which produces and markets devices, known as lithotripters, for the treatment of urinary tract stones by means of Extracorporeal Shockwave Lithotripsy technology. The EDAP stock yearly return is shown above.
The yearly return on the EDAP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EDAP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|